Know Cancer

or
forgot password

EVI-1 Expression in Pediatric AML With 11q23 Abnormalities


N/A
N/A
18 Years
Not Enrolling
Both
Leukemia

Thank you

Trial Information

EVI-1 Expression in Pediatric AML With 11q23 Abnormalities


OBJECTIVES:

- Examine mRNA from pediatric patients with acute myeloid leukemia with 11q23
translocations by reverse transcriptase-PCR to quantify expression of EVI1 splice
variants.

OUTLINE: Cryopreserved mRNA from diagnostic samples is analyzed for gene expression by
reverse transcriptase-PCR.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Diagnosis of pediatric acute myeloid leukemia with 11q23 abnormalities

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- Not specified

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Quantification of the expression of EVI1 splice variants

Safety Issue:

No

Principal Investigator

Amy Heerema-McKenney, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University

Authority:

United States: Federal Government

Study ID:

CDR0000664144

NCT ID:

NCT01057303

Start Date:

March 2010

Completion Date:

Related Keywords:

  • Leukemia
  • childhood acute myeloid leukemia/other myeloid malignancies
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid

Name

Location